KPV Research Overview
KPV Research Overview
Research-Only Notice & Compliance Boundary
This document is compiled strictly for educational and analytical reference purposes within laboratory, academic, and clinical research settings. The compounds discussed herein are supplied strictly as Research Use Only (RUO) chemicals and are not intended for human or veterinary consumption, diagnostic use, or therapeutic administration. Core Research does not provide dosing, reconstitution, or clinical administration guidelines.
Scientific Context and Research Background of KPV
KPV research peptide is a naturally derived tripeptide fragment that has attracted sustained scientific interest for its distinctive physicochemical compactness and its position within the broader landscape of endogenous regulatory peptides. Derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH), KPV encodes the amino acid triad Lysine-Proline-Valine and represents one of the smallest biologically characterised peptide entities currently under active pre-clinical investigation.
What makes KPV particularly compelling from a research standpoint is not merely its diminutive size — with a molecular weight of approximately 340 Da — but the disproportionate breadth of biological interactions that have been attributed to it in controlled laboratory settings. In the experience of researchers who work with small regulatory peptides daily, it is rare to encounter a three-residue sequence that commands such a concentrated body of mechanistic literature. The compound sits at an intellectually productive intersection: small enough to be synthesised with high purity and reproducibility, yet structurally specific enough to engage defined molecular targets in ways that larger peptides sometimes obscure through steric complexity.
Within the taxonomy of research peptides, KPV is broadly categorised under the repair and regulatory sub-class — a grouping that encompasses compounds whose pre-clinical profiles centre on modulation of cellular homeostatic processes rather than direct enzymatic catalysis or receptor agonism in the classical pharmacological sense. This categorisation, while operationally useful for laboratory procurement and storage planning, should not be interpreted as a clinical or therapeutic designation. It is a research classification that guides experimental design and analytical prioritisation.
The research significance of KPV has grown considerably over the past decade, driven in part by advances in peptide delivery science and in part by a renewed academic interest in endogenous short-chain peptides as models for understanding cellular signalling economy. As a research entity, KPV offers laboratories a tractable, well-documented, and analytically accessible subject — one whose Certificate of Analysis (CoA) parameters, storage requirements, and handling protocols are now sufficiently standardised to support rigorous, reproducible experimental programmes across multiple institutional settings.
Molecular Structure and Physicochemical Properties
Lys-Pro-Val
C16H30N4O4
342.44 Da
Lyophilised Powder
KPV — formally designated as the tripeptide H-Lys-Pro-Val-OH — is constituted by three proteinogenic amino acid residues arranged in a defined N-to-C terminal sequence: L-Lysine, L-Proline, and L-Valine. Its molecular formula is C16H30N4O4, yielding a calculated average molecular weight of approximately 342.44 Da. This places KPV firmly within the ultra-low molecular weight segment of the research peptide category — a physicochemical regime that carries significant implications for solubility behaviour, membrane permeability modelling, and analytical detection strategies.
The structural architecture of KPV is defined by several chemically notable features. The N-terminal lysine residue contributes a primary amine side chain (pKa ~10.5) and a free alpha-amino group, conferring a net positive charge at physiological pH values and endowing the molecule with considerable hydrophilicity. The central proline residue is structurally unique among the standard amino acids in that its side chain cyclises back onto the backbone nitrogen, forming a pyrrolidine ring. This imino acid character introduces a conformational rigidity into the peptide backbone at the Lys-Pro bond, restricting rotation and imposing a defined secondary structural preference — a feature that is widely considered to contribute to the relative proteolytic resistance of proline-containing short peptides compared to their non-proline counterparts. The C-terminal valine residue, a branched-chain aliphatic amino acid, introduces a degree of hydrophobic character that partially offsets the polarity of the lysine side chain, resulting in an amphipathic molecular profile that is analytically relevant when selecting chromatographic conditions for purity assessment.
From a synthesis perspective, KPV is produced via solid-phase peptide synthesis (SPPS) using standard Fmoc chemistry protocols. The relatively short chain length renders the synthesis straightforward in terms of coupling efficiency, and the absence of cysteine residues eliminates concerns regarding disulphide bridge formation or oxidative side reactions during synthesis and purification. High-performance liquid chromatography (HPLC) purification routinely achieves purity levels exceeding 98%, and the compound is characterised by mass spectrometry (typically ESI-MS or MALDI-TOF) to confirm molecular identity. These analytical parameters are documented in the Certificate of Analysis (CoA) that accompanies each research batch.
In its lyophilised form, KPV presents as a white to off-white amorphous powder. The compound demonstrates excellent aqueous solubility — a direct consequence of its net positive charge and the hydrophilic character of the lysine residue — and is readily reconstituted in sterile water or aqueous buffer systems for in-vitro experimental use. However, the same physicochemical properties that confer aqueous solubility also render the lyophilised powder highly hygroscopic, a characteristic that has direct and critical implications for storage protocol design, as discussed in detail in Section 4 of this overview. The isoelectric point (pI) of KPV is estimated at approximately 9.7, reflecting the dominance of the basic lysine side chain in determining the overall charge state of the molecule across the physiologically relevant pH range.
Pre-Clinical Research and Mechanism of Action
The pre-clinical research landscape surrounding KPV is anchored in its identity as a C-terminal tripeptide fragment of α-melanocyte-stimulating hormone (α-MSH), a tridecapeptide that has itself been the subject of extensive investigation for its roles in pigmentation, energy homeostasis, and — most pertinently for KPV research — the modulation of inflammatory signalling cascades. Early mechanistic work established that the anti-inflammatory activity attributed to α-MSH could be partially recapitulated by its C-terminal tripeptide KPV, raising the hypothesis that this minimal sequence encodes a functionally autonomous signalling motif capable of engaging relevant molecular targets independently of the full parent peptide.
At the molecular level, pre-clinical investigations have focused substantially on the interaction of KPV with the melanocortin receptor family — specifically MC1R and MC3R — as well as with intracellular signalling intermediaries downstream of these receptors. In-vitro studies conducted in macrophage and monocyte cell line models have reported that KPV exposure is associated with attenuation of pro-inflammatory cytokine production, including reductions
Comparative Analysis and Specifications
Positioning KPV within the broader landscape of research peptides requires a structured comparison of its defining technical parameters against accepted laboratory standards. The table below consolidates four critical specification domains — purity benchmarking, molecular weight classification, storage temperature requirements, and primary analytical verification methodology — each of which carries direct operational significance for laboratory procurement, quality assurance, and experimental reproducibility. Researchers designing multi-peptide comparative studies will find these parameters particularly useful when establishing internal controls and cross-referencing CoA documentation across supplier batches.
| Parameter | KPV Specification / Standard | Research Relevance |
|---|---|---|
| Purity Level (HPLC) | ≥98% by reverse-phase HPLC; CoA-verified per batch | Ensures minimal impurity interference in cytokine assays and receptor-binding studies; critical for reproducible in-vitro dose-response modelling |
| Molecular Weight Classification | 342.44 Da — ultra-low MW tripeptide segment (<500 Da threshold) | Sub-500 Da classification supports passive membrane permeability modelling; relevant to epithelial transport and nanoparticle encapsulation research programmes |
| Recommended Storage Temperature | −20 °C (lyophilised); −80 °C for extended archival; avoid repeated freeze-thaw cycles | Thermal stability data informs experimental scheduling; degradation at ambient temperature compromises purity and invalidates comparative analytical results |
| Primary Identity Verification Method | ESI-MS or MALDI-TOF mass spectrometry; confirmed [M+H]⁺ ion at m/z 343.45 | Mass spectrometric confirmation is the gold-standard identity check for tripeptides; distinguishes KPV from isobaric contaminants and synthesis by-products that HPLC alone may not resolve |
All specifications reflect research-grade supply standards. Parameters should be independently verified against the CoA issued with each specific batch prior to experimental use.
Regulatory Status and Safety Compliance
Governance Framework — Research Use Only Context
All laboratory activities involving KPV and analogous research peptides must be conducted within a clearly defined governance framework that satisfies both institutional and national regulatory obligations. In the United Kingdom, research institutions handling Research Use Only (RUO) chemical entities are subject to oversight by the Medicines and Healthcare products Regulatory Agency (MHRA) where applicable, and must operate in accordance with the principles set out under the Human Tissue Act 2004, the Health and Safety at Work Act 1974, and COSHH (Control of Substances Hazardous to Health) Regulations 2002. Researchers holding professional registration with the General Medical Council (GMC) or the Health and Care Professions Council (HCPC) are additionally bound by their respective codes of conduct, which explicitly prohibit the administration of unlicensed substances outside of formally approved clinical trial frameworks.
Adult and Child Safeguarding: Any research programme that involves human biological samples, participant recruitment, or observational data collection must comply with the safeguarding obligations established under the Care Act 2014 and the Children Act 1989. Principal investigators bear a duty of care to ensure that no research participant — adult or minor — is exposed to undue risk, coercion, or harm. Institutional safeguarding leads must be identified and accessible, and all staff involved in participant-adjacent research activities should hold current safeguarding training at the level appropriate to their role.
Data Protection and Information Governance: Research data generated in studies involving KPV — including participant metadata, biological sample records, and analytical outputs — must be managed in full compliance with the UK General Data Protection Regulation (UK GDPR) and the Data Protection Act 2018. Data minimisation principles apply; identifiable information should be pseudonymised at the earliest practicable stage of the research workflow. Electronic records must be stored on encrypted, access-controlled systems, and data retention schedules must be documented within the study’s data management plan.
Secure Reporting and Incident Escalation: Laboratories must maintain documented procedures for the reporting of adverse events, near-misses, and regulatory non-compliance incidents. These procedures should designate clear escalation pathways to institutional research governance offices, ethics committees, and — where applicable — the MHRA Yellow Card scheme. All personnel handling RUO compounds should be briefed on these pathways as part of their laboratory induction. Core Research supplies KPV exclusively for research purposes and does not assume liability for use outside the documented RUO framework.
Research Questions and Technical Support
What is the origin of the KPV peptide sequence?
KPV (Lys-Pro-Val) is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH), a tridecapeptide with established roles in pigmentation and inflammatory regulation. In our experience, researchers frequently underestimate how much functional specificity can reside within such a minimal endogenous sequence.
How should lyophilised KPV be stored to maintain research-grade integrity?
Lyophilised KPV should be stored at −20 °C in a desiccated, light-protected environment. For archival purposes exceeding six months, −80 °C is recommended. Repeated freeze-thaw cycling measurably degrades purity — a finding consistently observed during internal stability monitoring programmes.
What analytical methods are used to verify KPV identity and purity?
Identity is confirmed by ESI-MS or MALDI-TOF mass spectrometry, with purity assessed by reverse-phase HPLC (≥98%). Both results are documented in the batch-specific CoA. Researchers should cross-reference CoA data against their own in-house analytical verification before commencing experimental work.
Is KPV suitable for in-vitro cell culture studies?
Yes, KPV’s high aqueous solubility and sub-500 Da molecular weight make it well-suited to in-vitro cell culture applications. It reconstitutes readily in sterile water or PBS. Researchers working with macrophage and epithelial cell models report consistent handling behaviour across standard culture conditions.
Why does the proline residue matter structurally for KPV research?
Proline’s pyrrolidine ring restricts backbone rotation at the Lys-Pro bond, conferring conformational rigidity and relative proteolytic resistance. This structural feature is considered a key contributor to KPV’s stability in biological matrices — a property that meaningfully extends its utility in complex in-vitro experimental environments.
Can KPV be used for human or veterinary administration?
No. KPV is supplied exclusively as a Research Use Only (RUO) compound and is not approved, licensed, or intended for human or veterinary administration. Any use outside a formally governed laboratory research context falls outside the permitted scope of supply and contravenes applicable regulatory frameworks.
What receptor targets have been investigated in KPV pre-clinical studies?
Pre-clinical literature has focused primarily on melanocortin receptors MC1R and MC3R, alongside downstream NF-κB pathway intermediaries. Intracellular uptake mechanisms have also been investigated in epithelial models. Researchers new to this field consistently find the receptor-independent intracellular pathway literature particularly instructive for experimental design.